![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Show more
Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalization after 12 weeks of treatment...
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR Newswire NEW YORK, July 3, 2024 NEW YORK, July 3, 2024 /PRNewswire/ -- The Gross Law...
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyās management team will...
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR Newswire NEW YORK, June 28, 2024 NEW YORK, June 28, 2024 /PRNewswire/ -- The Gross Law...
GAITHERSBURG, Md., June 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Richard Eisenstadt, the Companyās Chief...
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT PR Newswire NEW YORK, June 25, 2024 NEW YORK, June 25, 2024 /PRNewswire/...
GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical...
GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc.Ā (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its...
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyās management team will...
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT PR Newswire NEW YORK, June 20, 2024 NEW YORK, June 20...
Period ā | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1557 | 2.3680608365 | 6.575 | 7.14 | 6.0905 | 2226136 | 6.42946883 | CS |
4 | 0.3407 | 5.33176838811 | 6.39 | 8.26 | 6.0905 | 3106406 | 7.00740879 | CS |
12 | -0.6793 | -9.1673414305 | 7.41 | 9.5 | 5.64 | 3562985 | 7.05225942 | CS |
26 | -2.6693 | -28.3968085106 | 9.4 | 14.84 | 5.64 | 4092583 | 8.70739362 | CS |
52 | 3.7207 | 123.611295681 | 3.01 | 14.84 | 2.09 | 5022191 | 7.49799447 | CS |
156 | -2.1393 | -24.1183765502 | 8.87 | 23.49 | 2.09 | 2688076 | 8.45849189 | CS |
260 | 4.3807 | 186.412765957 | 2.35 | 35.1 | 1.45 | 2297929 | 9.95944411 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions